Skip to main content

Advertisement

SpringerLink
Log in

Comparative evaluation of clinical and inflammatory factors in response to the pharmacological managements in metabolic syndrome

  • Original Article
  • Published:
International Journal of Diabetes in Developing Countries Aims and scope Submit manuscript

Abstract

Our study focused to assess the effect of various potential treatments on components of metabolic syndrome (MetS). This is a prospective, open-label, parallel group and randomized control trial of 90-day duration in which patients (n = 159) were randomly assigned in four groups to receive “diet and lifestyle modification” (n = 40), “metformin 500 mg twice daily” (n = 39), “pioglitazone 15 mg once daily” (n = 39), and “rosuvastatin 10 mg once daily” (n = 41). Clinical, biochemical, and inflammatory markers of each participant were evaluated. Fasting plasma glucose (FPG) level was lower in all except rosuvastatin group while HDL-cholesterol level increased in rosuvastatin group only (p < 0.05). Serum triglyceride was significantly and comparably decreased in both pioglitazone and rosuvastatin group (p < 0.05). Significant decrease in hsCRP and increase in serum adiponectin (p < 0.05) were reported in all the groups from baseline. The study can add a step forward in devising standard pharmacotherapeutic regimen beyond the current treatment modalities.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA- J Am Med Assoc. 2002;288:2709–16.

    Article  Google Scholar 

  2. Kaur J. A comprehensive review on metabolic syndrome. Cardiol Res Pract. 2014;11:943162.

    Google Scholar 

  3. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393–403.

    Article  CAS  PubMed  Google Scholar 

  4. Durbin RJ. Thiazolidinedione therapy in the prevention/delay of type 2 diabetes in patients with impaired glucose tolerance and insulin resistance. Diabetes Obes Metab. 2004;6:280–5.

    Article  CAS  PubMed  Google Scholar 

  5. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air force/Texas coronary atherosclerosis prevention study. JAMA- J Am Med Assoc. 1998;279:1615–22.

    Article  CAS  Google Scholar 

  6. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian cardiac outcomes trial–lipid lowering arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361:1149–58.

    Article  CAS  PubMed  Google Scholar 

  7. Cohen J. A power primer. Psychol Bull. 1992;112:155–9.

    Article  CAS  PubMed  Google Scholar 

  8. Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care. 2007;30(1):162–72.

    Article  CAS  PubMed  Google Scholar 

  9. Kadoglou NPE, Vrabas IS, Sailor N, Kapelouzou A, Fotiadis G, Noussios G, et al. Exercise ameliorates serum MMP-9 and TIMP-2 levels in patients with type 2 diabetes. Diabetes & Metabolism. 2010;36:144–51.

    Article  CAS  Google Scholar 

  10. Naples M, Federico L, Xu E, Nelken J, Adeli K. Effect of rosuvastatin on insulin sensitivity in an animal model of insulin resistance: evidence for statin-induced hepatic insulin sensitization. Atherosclerosis. 2008;198:94–103.

    Article  CAS  PubMed  Google Scholar 

  11. Sharma PK, Bhansali A, Sialy R, Malhotra S, Pandhi P. Effects of pioglitazone and metformin on plasma adiponectin in newly detected type 2 diabetes mellitus. Clin Endocrinol. 2006;65:722–8.

    Article  CAS  Google Scholar 

  12. Esteghamati A, Ghasemiesfe M, Mousavizadeh M, Noshad S, Nakhjavani M. Pioglitazone and metformin are equally effective in reduction of chemerin in patients with type 2 diabetes. Diabetes Investigation. 2014;5:327–32.

    Article  CAS  Google Scholar 

  13. Kargiotis K, Katsiki N, Athyros VG, Giouleme O, Patsiaoura K, Katsiki E, et al. Effect of rosuvastatin on non-alcoholic steatohepatitis in patients with metabolic syndrome and hypercholesterolaemia: a preliminary report. Curr Vasc Pharmacol. 2014;12(3):505–11.

    Article  CAS  PubMed  Google Scholar 

  14. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care. 2002; 25(12):2165–71.

  15. Stalenhoff AFH, Ballantyne CM, Sarti C, Murin J, Tonstad S, Rose H, Wilpshaar W. A comparative study with rosuvastatin in subjects with metabolic syndrome: results of the COMETS study. Eur Heart J. 2005;26:2664–72.

    Article  Google Scholar 

  16. Simsek S, Schalkwijk CG, Wolffenbuttel BH. Effects of rosuvastatin and atorvastatin on glycaemic control in type 2 diabetes—the CORALL study. Diabet Med. 2012;29(5):628–31.

    Article  CAS  PubMed  Google Scholar 

  17. Qu H, Xiao Y, Jiang G, Wang Z, Zhang Y, Zhang M. Effect of atorvastatin versus rosuvastatin on levels of serum lipids, inflammatory markers and adiponectin in patients with hypercholesterolemia. Pharm Res. 2009;26(4):958–64.

    Article  CAS  PubMed  Google Scholar 

  18. Siddiqi SS. Misbahuddin, Ahmad F, Rahman SZ, khan AU. Dyslipidemic drugs in metabolic syndrome. Indian J Endocrinol Metab. 2013;17(3):472–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Libby P, Bonow RO, Mann DL, Zipes DP, Braunwald E. Braunwald’s heart disease: a textbook of cardiovascular medicine. USA: Saunders; 2007.

    Google Scholar 

  20. Shimizu T, Miura S, Tanigawa H, Kuwano T, Zhang B, Uehara Y, Saku K. Rosuvastatin activates ATP-binding cassette transporter A1-dependent efflux ex vivo and promotes reverse cholesterol transport in macrophage cells in mice fed a high-fat diet. Arterioscler Thromb Vasc Biol. 2014;34(10):2246–53.

    Article  CAS  PubMed  Google Scholar 

  21. Szapary PO, Bloedon LT, Samaha FF, Duffy D, Wolfe ML, Soffer D. Effects of pioglitazone on lipoproteins, inflammatory markers, and Adipokines in Nondiabetic patients with metabolic syndrome. Arterioscler Thromb Vasc Biol. 2006;26:182–8.

    Article  CAS  PubMed  Google Scholar 

  22. Bersot TP. Drug therapy for hypercholesterolemia and dyslipidemia. In: Brunton LL, Chabner BA, Knollmann BC, editors. Goodman and Gilman’s: the pharmacological basis of therapeutics. USA: Academic; 2011. p. 877–908.

    Google Scholar 

  23. Hunningshake DB, Stein EA, Bays HE, Rader DJ, Chitra RR, Simonson SG, et al. Rosuvastatin improves the atherogenic and atheroprotective lipid profiles in patients with hypertriglyceridemia. Coron Artery Dis. 2004;15(2):115–23.

    Article  Google Scholar 

  24. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation. 2003;107:363–9.

    Article  PubMed  Google Scholar 

  25. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105:1135–43.

    Article  CAS  PubMed  Google Scholar 

  26. Povel CM, Beulens JW, Schouw YTV, Dollé MET, Spijkerman AMW, Verschuren WMM, Feskens EJM, Boer JMA. Metabolic syndrome model definitions. Predicting type 2 diabetes and cardiovascular disease. Diabetes Care. 2013;36:362–8.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Ciaraldi TP, Kong APS, Chu NV, Kim DD, Baxi S, Loviscach M, Plodkowski R, Reitz R, Caulfield M, Mudaliar S, Henry RR. Regulation of glucose transport and insulin signaling by troglitazone or metformin in adipose tissue of type 2 diabetic subjects. Diabetes. 2002;51:30–6.

    Article  CAS  PubMed  Google Scholar 

  28. Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev. 2005;26:439–51.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

Authors are thankful to Mr. VK Saini and Mr. Durgesh Yadav for the technical support. Authors are also thankful to the staff of the department of medicine for the recruitment of patients. The study was not supported by any external funding agency.

Author information

Authors and Affiliations

  1. Department of Pharmacology and Therapeutics, King George’s Medical University, Lucknow, UP, 226003, India

    Arpit Jain, Suraj S. Yadav, Devendra K. Katiyar & Sanjay Khattri

  2. Department of Pharmacology, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India

    Pradeep Dwivedi

  3. Department of Medicine, King George’s Medical University, Lucknow, UP, 226003, India

    Kauser Usman

Authors
  1. Arpit Jain
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Suraj S. Yadav
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Pradeep Dwivedi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Devendra K. Katiyar
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kauser Usman
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Sanjay Khattri
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sanjay Khattri.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Additional information

Suraj S. Yadav has Equal contribution as first author

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jain, A., Yadav, S.S., Dwivedi, P. et al. Comparative evaluation of clinical and inflammatory factors in response to the pharmacological managements in metabolic syndrome. Int J Diabetes Dev Ctries 37, 464–469 (2017). https://doi.org/10.1007/s13410-016-0519-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13410-016-0519-0

Keywords

Search

Navigation